Rothschild & Co Asset Management US’s Ironwood Pharmaceuticals IRWD Stock Holding History

Rothschild & Co Asset Management US’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,465,316	Closed	-$18.4M	–	355
2017 Q4	$18.4M	Sell	1,465,316 -45,656	-3%	-$596K	0.19%	204
2017 Q3	$20M	Buy	1,510,972 +79,885	+6%	+$1.1M	0.22%	179
2017 Q2	$22.6M	Buy	1,431,087 +37,552	+3%	+$546K	0.26%	157
2017 Q1	$19.9M	Buy	1,393,535 +154,157	+12%	+$2.11M	0.23%	175
2016 Q4	$15.9M	Buy	1,239,378 +1,215,996	+5,201%	+$15.4M	0.2%	192
2016 Q3	$311K	Buy	+23,382	New	+$273K	0.01%	511

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Rothschild & Co Asset Management US's IRWD Position: Q1 2018 in Review

Rothschild & Co Asset Management US sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2018, closing a stake of 1,465,316 shares — an estimated $18.4M sold.

Rothschild & Co Asset Management US first reported a position in IRWD in Q3 2016 and held it in 6 quarters. The position peaked at $22.6M in Q2 2017. 149 funds tracked by Wall St. Rank hold IRWD as of Q1 2018.

Rothschild & Co Asset Management US reported no remaining Ironwood Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Rothschild & Co Asset Management US sold 1,465,316 Ironwood Pharmaceuticals shares in Q1 2018, an estimated $18.4M.
Rothschild & Co Asset Management US first reported a position in Ironwood Pharmaceuticals in Q3 2016 and held it in 6 quarters.
Rothschild & Co Asset Management US's Ironwood Pharmaceuticals position peaked at $22.6M in Q2 2017.
149 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2018.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2018, filed 8 May 2018.